Nothing Special   »   [go: up one dir, main page]

SE9101472D0 - Galanin antagonist - Google Patents

Galanin antagonist

Info

Publication number
SE9101472D0
SE9101472D0 SE9101472A SE9101472A SE9101472D0 SE 9101472 D0 SE9101472 D0 SE 9101472D0 SE 9101472 A SE9101472 A SE 9101472A SE 9101472 A SE9101472 A SE 9101472A SE 9101472 D0 SE9101472 D0 SE 9101472D0
Authority
SE
Sweden
Prior art keywords
galanin
pro
antagonist
enkephalin
leu
Prior art date
Application number
SE9101472A
Other languages
English (en)
Inventor
T Bartfai
Original Assignee
Trion Forskning & Utveckling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trion Forskning & Utveckling filed Critical Trion Forskning & Utveckling
Priority to SE9101472A priority Critical patent/SE9101472D0/sv
Publication of SE9101472D0 publication Critical patent/SE9101472D0/sv
Priority to YU50592A priority patent/YU50592A/sh
Priority to KR1019930703433A priority patent/KR100221769B1/ko
Priority to HU9303236A priority patent/HUT65810A/hu
Priority to AU17858/92A priority patent/AU664180B2/en
Priority to SG1996005509A priority patent/SG43921A1/en
Priority to PL92301284A priority patent/PL171497B1/pl
Priority to CA002109503A priority patent/CA2109503A1/en
Priority to PCT/SE1992/000316 priority patent/WO1992020709A1/en
Priority to DE0585300T priority patent/DE585300T1/de
Priority to DE69217937T priority patent/DE69217937T2/de
Priority to DK92910508.8T priority patent/DK0585300T3/da
Priority to SK1277-93A priority patent/SK127793A3/sk
Priority to EP92910508A priority patent/EP0585300B1/en
Priority to CS932422A priority patent/CZ242293A3/cs
Priority to EP19920850108 priority patent/EP0514361A1/en
Priority to ES92910508T priority patent/ES2098510T3/es
Priority to JP4510575A priority patent/JPH06507629A/ja
Priority to AT92910508T priority patent/ATE149525T1/de
Priority to IS3866A priority patent/IS3866A/is
Priority to SI9200081A priority patent/SI9200081B/sl
Priority to IE155592A priority patent/IE921555A1/en
Priority to NO934098A priority patent/NO934098L/no
Priority to FI935010A priority patent/FI935010A0/fi
Priority to EE9400346A priority patent/EE9400346A/xx
Priority to US08/468,514 priority patent/US5576296A/en
Priority to GR970400812T priority patent/GR3023150T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9101472A 1991-05-15 1991-05-15 Galanin antagonist SE9101472D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE9101472A SE9101472D0 (sv) 1991-05-15 1991-05-15 Galanin antagonist
YU50592A YU50592A (sh) 1991-05-15 1992-05-13 Antagonisti galanina
AT92910508T ATE149525T1 (de) 1991-05-15 1992-05-14 Galaninantagonist
SK1277-93A SK127793A3 (en) 1991-05-15 1992-05-14 Galanin antagonist
EP19920850108 EP0514361A1 (en) 1991-05-15 1992-05-14 Galanin antagonist
AU17858/92A AU664180B2 (en) 1991-05-15 1992-05-14 Galanin antagonist
SG1996005509A SG43921A1 (en) 1991-05-15 1992-05-14 Galanin antagonist
PL92301284A PL171497B1 (pl) 1991-05-15 1992-05-14 Sposób wytwarzania peptydów PL PL PL
CA002109503A CA2109503A1 (en) 1991-05-15 1992-05-14 Galanin antagonist
PCT/SE1992/000316 WO1992020709A1 (en) 1991-05-15 1992-05-14 Galanin antagonist
DE0585300T DE585300T1 (de) 1991-05-15 1992-05-14 Galaninantagonist.
DE69217937T DE69217937T2 (de) 1991-05-15 1992-05-14 Galaninantagonist
DK92910508.8T DK0585300T3 (da) 1991-05-15 1992-05-14 Galaninantagonist
KR1019930703433A KR100221769B1 (ko) 1991-05-15 1992-05-14 갈라닌 길항제
EP92910508A EP0585300B1 (en) 1991-05-15 1992-05-14 Galanin antagonist
CS932422A CZ242293A3 (en) 1991-05-15 1992-05-14 Galanine antagonist
HU9303236A HUT65810A (en) 1991-05-15 1992-05-14 Process for producing galanin-antagonistic peptides
ES92910508T ES2098510T3 (es) 1991-05-15 1992-05-14 Antagonista de galanina.
JP4510575A JPH06507629A (ja) 1991-05-15 1992-05-14 ガラニンアンタゴニスト
SI9200081A SI9200081B (sl) 1991-05-15 1992-05-15 Galaninski antagonist
IS3866A IS3866A (is) 1991-05-15 1992-05-15 Efni með gagnstæða verkun við Galanín
IE155592A IE921555A1 (en) 1991-05-15 1992-07-01 Galanin antagonist
NO934098A NO934098L (no) 1991-05-15 1993-11-12 Galaninantagonist
FI935010A FI935010A0 (fi) 1991-05-15 1993-11-12 Galaninantagonist
EE9400346A EE9400346A (et) 1991-05-15 1994-11-03 Galaniini antagonist, selle valmistamise protsess ja teda sisaldavad ravimpreparaadid
US08/468,514 US5576296A (en) 1991-05-15 1995-06-06 Galanin antagonist
GR970400812T GR3023150T3 (en) 1991-05-15 1997-04-15 Galanin antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101472A SE9101472D0 (sv) 1991-05-15 1991-05-15 Galanin antagonist

Publications (1)

Publication Number Publication Date
SE9101472D0 true SE9101472D0 (sv) 1991-05-15

Family

ID=20382742

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9101472A SE9101472D0 (sv) 1991-05-15 1991-05-15 Galanin antagonist

Country Status (24)

Country Link
EP (2) EP0514361A1 (sv)
JP (1) JPH06507629A (sv)
KR (1) KR100221769B1 (sv)
AT (1) ATE149525T1 (sv)
AU (1) AU664180B2 (sv)
CA (1) CA2109503A1 (sv)
CZ (1) CZ242293A3 (sv)
DE (2) DE585300T1 (sv)
DK (1) DK0585300T3 (sv)
EE (1) EE9400346A (sv)
ES (1) ES2098510T3 (sv)
FI (1) FI935010A0 (sv)
GR (1) GR3023150T3 (sv)
HU (1) HUT65810A (sv)
IE (1) IE921555A1 (sv)
IS (1) IS3866A (sv)
NO (1) NO934098L (sv)
PL (1) PL171497B1 (sv)
SE (1) SE9101472D0 (sv)
SG (1) SG43921A1 (sv)
SI (1) SI9200081B (sv)
SK (1) SK127793A3 (sv)
WO (1) WO1992020709A1 (sv)
YU (1) YU50592A (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107400A0 (en) * 1992-11-10 1994-01-25 Cortech Inc Bradykinin antagonists
FR2716205B1 (fr) 1994-02-17 1996-04-12 Rhone Poulenc Rorer Sa Récepteur galanine, acides nucléiques, cellules transformées et utilisations.
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
ES2112238T1 (es) 1996-01-24 1998-04-01 Synaptic Pharma Corp Acido nucleico.
PT918455E (pt) * 1996-07-24 2003-09-30 Neurotargets Ltd Utilizacao de galanina para reparar lesoes dos nervos
US6329197B2 (en) 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
EP0998577B1 (en) * 1997-07-24 2004-10-27 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
ATE294816T1 (de) 1998-03-25 2005-05-15 Takeda Pharmaceutical Neue, physiologisch aktive peptide und ihre verwendung.
DE60035991D1 (de) * 1999-05-21 2007-09-27 Ortho Mcneil Pharm Inc 1,4-dithiin und 1,4-dithiepin-1,1,4,4, tetroxid derivate verwendbar als human galanin receptor antagonisten
US6407136B1 (en) 1999-05-21 2002-06-18 Ortho-Mcneil Pharmaceutical, Inc. 1,4-dithiin and 1,4-dithiepin-1,1,4,4, tetroxide derivatives useful as antagonists of the human galanin receptor
EP1089439A1 (en) * 1999-09-28 2001-04-04 TELEFONAKTIEBOLAGET L M ERICSSON (publ) Interleaver and method for interleaving an input data bit sequence using a coded storing of symbol and additional information
US7220775B2 (en) 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain
CA2580690A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
EP2545933A3 (en) 2006-01-05 2013-04-24 University Of Utah Research Foundation Methods and compositions related to improving properties of pharmacological agents targeting nervous system
WO2010028673A1 (en) * 2008-09-09 2010-03-18 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP2014501248A (ja) 2010-12-15 2014-01-20 ニューロアジュヴァンツ，インコーポレイテッド ニューロペプチド類似体、組成物、及び疼痛の治療方法
HUE033371T2 (en) 2013-03-21 2017-11-28 Sanofi Aventis Deutschland Process for the preparation of peptide products containing a ring imide
ES2623979T3 (es) 2013-03-21 2017-07-12 Sanofi-Aventis Deutschland Gmbh Síntesis de productos peptídicos que contienen hidantoína
CN110055340B (zh) * 2019-04-11 2021-01-01 中国农业大学 一种食品中牛源成分快速检测方法及试剂盒

Also Published As

Publication number Publication date
CA2109503A1 (en) 1992-11-16
YU50592A (sh) 1994-09-09
PL171497B1 (pl) 1997-05-30
CZ242293A3 (en) 1994-07-13
SI9200081B (sl) 2000-08-31
KR100221769B1 (ko) 1999-10-01
WO1992020709A1 (en) 1992-11-26
IS3866A (is) 1992-11-16
FI935010A (fi) 1993-11-12
GR3023150T3 (en) 1997-07-30
EP0585300B1 (en) 1997-03-05
EP0585300A1 (en) 1994-03-09
NO934098D0 (no) 1993-11-12
FI935010A0 (fi) 1993-11-12
AU664180B2 (en) 1995-11-09
DE69217937T2 (de) 1997-06-19
EP0514361A1 (en) 1992-11-19
SG43921A1 (en) 1997-11-14
EE9400346A (et) 1996-04-15
HUT65810A (en) 1994-07-28
DE69217937D1 (de) 1997-04-10
SI9200081A (en) 1992-12-31
DK0585300T3 (da) 1997-09-01
IE921555A1 (en) 1992-11-18
ES2098510T3 (es) 1997-05-01
NO934098L (no) 1993-11-12
AU1785892A (en) 1992-12-30
SK127793A3 (en) 1994-04-06
ATE149525T1 (de) 1997-03-15
DE585300T1 (de) 1994-06-16
JPH06507629A (ja) 1994-09-01

Similar Documents

Publication Publication Date Title
ATE149525T1 (de) Galaninantagonist
EP1233013A4 (en) phenylalanine derivatives
TW349867B (en) Pharmaceutical composition for inducing a cytotoxic T-lymphocyte responses
FI910286A0 (fi) Analoger av humant insulin och preparat innehaollande dessa.
LU91449I2 (fr) "panitumumab en combinaison avec un agent anti-néoplastique"
DE69028671D1 (de) Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung
DE60143984D1 (de) Neue phenylalanin-derivate
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
DE69006676D1 (de) Tripeptidverbindungen und ihre pharmazeutische Anwendung als Immunmodulatoren.
ATE253590T1 (de) Peptide, bronchodilator und den blutstrom verbesserndes mittel
DE59409140D1 (de) Cyclosporin(e) enthaltende o/w Emulsion zur oralen Verabreichung
ES2162078T3 (es) Compuestos terapeuticos.
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.
RU93058426A (ru) Антогонист галанина, способ его получения, пептид, фармацевтический состав и способ лечения
NO880831D0 (no) Rekombinant human vevsplasminogen-aktivatorblanding.
IT8804860A0 (it) Procedimento per il recupero di calore, con eventuale recupero od uso dell'umidita', ceduto direttamente o indirettamente dal corpo umano e dispositivo per la sua attuazione.
KR900001677U (ko) 플로어(floor) 콘센트의 출몰장치
IT8922251A0 (it) Peptide sintetico derivato dalla lipocortina v umana e suo impiego
IT9046503A0 (it) Manto rosso 2000
GB8903389D0 (en) Accessories for use by motorists and others such as ramblers,walkers and climbers
KR910006620U (ko) 모니터용 리버 풋(Rubber Foot)
KR900013827U (ko) 모니터의 보조 휘도 조정회로
KR920010055U (ko) 모니터의 인터페이스 회로